PerkinElmer acquires Oxford Immunotec Global PLC

A global leader pledged to innovating for a healthier world, PerkinElmer, has announced the acquisition of Oxford Immunotec Global PLC.

Oxford Immunotec, headquartered in Abingdon, UK, is a global leader of proprietary test kits for the most advanced tuberculosis.

PerkinElmer president and chief executive officer, Prahlad Singh, stated: “Oxford Immunotec’s global role in fighting tuberculosis – particularly its trademark product – the T-SPOT®.TB test, and the operations it has built are remarkable. We recognize the distinct clinical and logistical advantages of the test and see a great opportunity to leverage our automation capabilities and commercial channel access to bring tuberculosis testing to more customers around the world.”